{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:04:36Z","timestamp":1785762276073,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013143","name":"National Natural Science Foundation of China-Shandong Joint Fund for Marine Science Research Centers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013143","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.nut.2024.112462","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T22:48:24Z","timestamp":1712357304000},"page":"112462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients"],"prefix":"10.1016","volume":"124","author":[{"given":"Haoqian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Butuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2231-6642","authenticated-orcid":false,"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.nut.2024.112462_bib0001","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2018-0609","article-title":"KEYNOTE-590: phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer","volume":"15","author":"Kato","year":"2019","journal-title":"Future Oncol"},{"issue":"26","key":"10.1016\/j.nut.2024.112462_bib0002","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.nut.2024.112462_bib0003","doi-asserted-by":"crossref","first-page":"TPS193","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS193","volume":"36","author":"Ajani","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10302","key":"10.1016\/j.nut.2024.112462_bib0004","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.nut.2024.112462_bib0005","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.nut.2024.112462_bib0006","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.nut.2024.112462_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-na\u00efve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.nut.2024.112462_bib0008","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.apsb.2021.03.008","article-title":"Advances and challenges in the treatment of esophageal cancer","volume":"11","author":"He","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10.1016\/j.nut.2024.112462_bib0009","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrclinonc.2015.200","article-title":"Cachexia in patients with oesophageal cancer","volume":"13","author":"Anandavadivelan","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nut.2024.112462_bib0010","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.nut.2024.112462_bib0011","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00535-013-0787-0","article-title":"Cancer cachexia\u2013pathophysiology and management","volume":"48","author":"Suzuki","year":"2013","journal-title":"J Gastroenterol"},{"issue":"2","key":"10.1016\/j.nut.2024.112462_bib0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.nut.2024.112462_bib0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00262-021-02997-2","article-title":"Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab","volume":"71","author":"Jo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.nut.2024.112462_bib0014","article-title":"Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC","volume":"1","author":"Miyawaki","year":"2020","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.nut.2024.112462_bib0015","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00520-021-06572-4","article-title":"Impact of weight loss on treatment with PD-1\/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer","volume":"30","author":"Miyawaki","year":"2022","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.nut.2024.112462_bib0016","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1950411","article-title":"Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study","volume":"10","author":"Morimoto","year":"2021","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.nut.2024.112462_bib0017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nut.2024.112462_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106767","article-title":"Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis","volume":"104","author":"Wang","year":"2022","journal-title":"Int J Surg"},{"issue":"6","key":"10.1016\/j.nut.2024.112462_bib0019","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/ijms22062890","article-title":"Cachexia as evidence of the mechanisms of resistance and tolerance during the evolution of cancer disease","volume":"22","author":"Maccio","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.nut.2024.112462_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40880-019-0427-z","article-title":"The immune landscape of esophageal cancer","volume":"39","author":"Huang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"issue":"8","key":"10.1016\/j.nut.2024.112462_bib0021","doi-asserted-by":"crossref","first-page":"535","DOI":"10.18632\/aging.100482","article-title":"Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism","volume":"4","author":"Lutz","year":"2012","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.nut.2024.112462_bib0022","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1759-7714.12965","article-title":"Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: a \u201chypothesis-generator\u201d preliminary report","volume":"10","author":"Cortellini","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.nut.2024.112462_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2021.111345","article-title":"Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: a comprehensive systematic review and meta-analysis","volume":"90","author":"Deng","year":"2021","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.nut.2024.112462_bib0024","doi-asserted-by":"crossref","first-page":"144","DOI":"10.6004\/jnccn.2020.7615","article-title":"Cachexia and dietetic interventions in patients with esophagogastric cancer: a multicenter cohort study","volume":"19","author":"Dijksterhuis","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.nut.2024.112462_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines\u2606","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.nut.2024.112462_bib0026","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clnesp.2021.02.017","article-title":"Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy","volume":"43","author":"Baldessari","year":"2021","journal-title":"Clin Nutr ESPEN"},{"issue":"2","key":"10.1016\/j.nut.2024.112462_bib0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cyto.2012.01.015","article-title":"Inflammation and ovarian cancer","volume":"58","author":"Macci\u00f2","year":"2012","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.nut.2024.112462_bib0028","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","article-title":"Metabolic instruction of immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.nut.2024.112462_bib0029","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1017\/S0029665118000186","article-title":"Barriers to cancer nutrition therapy: excess catabolism of muscle and adipose tissues induced by tumour products and chemotherapy","volume":"77","author":"Schiessel","year":"2018","journal-title":"Proc Nutr Soc"},{"issue":"1","key":"10.1016\/j.nut.2024.112462_bib0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jcsm.12360","article-title":"Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism","volume":"10","author":"Pin","year":"2019","journal-title":"J Cachexia Sarcopenia Muscle"}],"container-title":["Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900724001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899900724001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T06:16:48Z","timestamp":1718432208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899900724001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":30,"alternative-id":["S0899900724001126"],"URL":"https:\/\/doi.org\/10.1016\/j.nut.2024.112462","relation":{},"ISSN":["0899-9007"],"issn-type":[{"value":"0899-9007","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients","name":"articletitle","label":"Article Title"},{"value":"Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nut.2024.112462","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112462"}}